Novartis Diabetes Drug Flunks Clinical Trial

Boston (DbTechNo) – Results of a new study show that the diabetes drug Starlix and the blood pressure drug Diovan do not reduce the risk of heart disease in diabetes patients.

Both drugs are manufactured by Novartis and when tested against placebo pills, they both performed very poorly.

In a study featuring more than 9000 patients, those taking Diovan, were 14% less likely to see their diabetes progress, but were at no reduced risk of developing serious heart problems.

Starlix also performed very poorly, and was shown to be ineffective when it came to reducing the progression of diabetes in patients.

“Most experts believed that nateglinide would prevent diabetes and that valsartan would reduce cardiovascular events in this population,” said Dr. Robert Califf, the study’s lead investigator.

This appears not to be the case however, as the study finding proves that the drugs may not be the best option for diabetics.

• Share
• Tweet
• "&title=""">